News

EU monitors bioeconomy
Enlarge image

PolicyEU

EU monitors bioeconomy

19.02.2013 - The European Commission has announced it will launch an observatory to map progress and impact of the development of the EU's bioeconomy.

The observatory, which is part of the EC's bioeconomy action plan, will gather data to follow the evolution of markets, to map EU, national and regional bioeconomy policies, research and innovation capacities, and the scale of related public and private investments. The Commission's in-house science service JRC will run the new resource.

"It's now one year since we launched our bioeconomy strategy“, said Research Commissioner Máire Geoghegan-Quinn in Brussels. „We are now seeing Member States seize the opportunity offered by the transition to a post-petroleum economy based on smart use of resources from land and sea. It's essential that they do because it will be good for our environment, our food and energy security, and for Europe's competitiveness in the future. This observatory will help keep the momentum going."

The observatory will start its 3-year term in March 2013 with the aim of making the data it will collect publicly available through a dedicated web portal in 2014. In this way, the observatory will support the regional and national bioeconomy strategies now being developed by EU Member States. The observatory will track a number of performance measures, including economic and employment indicators, innovation indicators, and measures of productivity, social wellbeing and environmental quality. It will also provide a "technology watch” and “policy watch” and will follow the development of science and technology.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/commission-monitors-bioeconomy.html

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KAROLINSKA (S)12.95 SEK8.37%
  • IXICO (UK)35.50 GBP5.97%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • MEDIGENE (D)9.65 EUR-10.32%
  • SERODUS (N)3.08 NOK-8.88%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • IXICO (UK)35.50 GBP57.8%
  • DBV TECHNOLOGIES (F)75.75 EUR43.9%
  • ADOCIA (F)88.67 EUR28.9%

FLOP

  • BIOTEST (D)25.26 EUR-64.3%
  • BIOTECH PHARMACON (N)9.44 NOK-47.6%
  • TRANSGENE (F)2.95 EUR-39.4%

TOP

  • ADOCIA (F)88.67 EUR532.9%
  • VERONA PHARMA (UK)4.88 GBP324.3%
  • FORMYCON (D)28.20 EUR305.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEOVACS (F)1.05 EUR-69.6%
  • BIOTEST (D)25.26 EUR-69.3%

No liability assumed, Date: 27.07.2015